EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond Docetaxel: Targeting Resistance Pathways in Prostate Cancer Treatment

Tayo Alex Adekiya

BioChem · 01.08.2025 · 5 (3) · 24

DOI: 10.3390/biochem5030024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioChem, online erschienen am 01.08.2025. Verfasst von Tayo Alex Adekiya. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer continues to be the most common cause of cancer-related disease and mortality among men worldwide, especially in the advanced stages, notably metastatic castration-resistant prostate cancer (mCRPC), which poses significant treatment challenges. Docetaxel, a widely used chemotherapeutic agent, has long served as the standard treatment, offering survival benefits and mitigation. However, its clinical impact is frequently undermined by the development of chemoresistance, which is a formidable challenge that leads to treatment failure and disease progression. The mechanisms driving docetaxel resistance are diverse and complex, encompassing modifications in androgen receptor signaling, drug efflux transporters, epithelial-mesenchymal transition (EMT), microtubule alterations, apoptotic pathway deregulation, and tumor microenvironmental influences. Recent evidence suggests that extracellular RNAs influence drug responses, further complicating the resistance landscape. This review offers a broad discussion on the mechanisms of resistance and explores novel therapeutic approaches to address them. These include next-generation taxanes, targeted molecular inhibitors, immunotherapies, and combination regimens that can be designed to counteract specific resistance pathways. By broadening our understanding of docetaxel resistance, this review highlights potential strategies to improve therapeutic efficacy and the potential to enhance outcomes in patients with advanced treatment-resistant prostate cancer.

Zitieren

APA

Adekiya, T. A. (2025). Beyond Docetaxel: Targeting Resistance Pathways in Prostate Cancer Treatment. BioChem, 5(3), 24. https://doi.org/10.3390/biochem5030024

Vancouver

Adekiya TA. Beyond Docetaxel: Targeting Resistance Pathways in Prostate Cancer Treatment. BioChem. 2025;5(3):24. doi:10.3390/biochem5030024

BibTeX
@article{Adekiya2025,
  author = {Adekiya, Tayo Alex},
  title = {Beyond Docetaxel: Targeting Resistance Pathways in Prostate Cancer Treatment},
  journal = {BioChem},
  year = {2025},
  volume = {5},
  number = {3},
  pages = {24},
  doi = {10.3390/biochem5030024}
}
Kostenlos starten →